Literature DB >> 5151819

Forty-four months' experience in the treatment of leprosy with clofazimine (Lamprene (Geigy)).

E J Schulz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5151819     DOI： 10.5935/0305-7518.19710021

Source DB:  PubMed          Journal:  Lepr Rev        ISSN： 0305-7518            Impact factor:   0.537


× No keyword cloud information.
  6 in total

1.  Prooxidative activities of 10 phenazine derivatives relative to that of clofazimine.

Authors:  B M Zeis; R Anderson; J F O'Sullivan
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

2.  Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy.

Authors:  C E van Rensburg; E M Gatner; F M Imkamp; R Anderson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

3.  Phagocytosis and intracellular degradation of 125I-labelled immune complexes by Clofazimine treated macrophage cultures.

Authors:  J Sarracent; C M Finlay
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

4.  Identification of crystals of the rimino-phenazine compound B663 (Lamprene: clofazimine) in mouse spleen macrophages by thin layer chromatography and mass spectrum analysis.

Authors:  R T Aplin; A C McDougall
Journal:  Experientia       Date:  1975-04-15

Review 5.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro.

Authors:  R Anderson
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.